Cardiovascular Devices Market Analysis by Top Companies, New Technology, Demand and Opportunity Analysis
The increasing incidence of heart diseases is a notable factor driving
the growth of the global cardiovascular devices market. According to the
Centers for Disease Control and Prevention (CDC), coronary heart disease is the
most common type of heart diseases which is responsible for over 370,000 deaths
annually, in the U.S. Cardiovascular diseases mainly include coronary artery
diseases (CAD) such as angina and myocardial infarction (commonly known as a
heart attack). Stroke, heart failure, hypertensive heart disease, rheumatic
heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, and
venous thrombosis are some other types of cardiovascular diseases.
On the basis of product, the cardiovascular devices market has been
categorized into cardiovascular monitoring and diagnostic devices, coronary
stents, pacemakers, defibrillators, interventional cardiac devices, heart
valves, cardiac ablation catheters, ventricular assist devices, and other
devices. These devices are majorly used in the treatment of coronary heart
disease, stroke, cerebrovascular diseases, rheumatic heart disease, and sudden
cardiac arrest.
Access report
overview: https://www.psmarketresearch.com/market-analysis/cardiovascular-devices-market
Hospitals, ambulatory surgery centers, and diagnostic clinics are the
primary end users in the cardiovascular devices market. Among these, hospitals
hold the largest share in this market and are expected to maintain this trend
during the forecast period. Increasing patient base and large presence of
skilled professionals in the hospital settings have been supporting the growth
of this end-user category. Other than above mentioned end users, cardiovascular
devices are also used in prehospital settings, at-home, schools, and
workplaces.
North America is expected to lead the global cardiovascular devices
market in the coming years, mainly due to the increasing awareness about
various heart diseases, and growing obese population in the region. In
addition, high disposable income and favorable reimbursement policies are also
supporting the growth of the market in the region. Europe is expected to hold
the second largest position in the global market, with Germany, France, and the
U.K. holding a substantial share in the European cardiovascular devices market.
Download Free
Sample of This Research Report : https://www.psmarketresearch.com/market-analysis/cardiovascular-devices-market/report-sample
Due to the leftover scars and pain caused by traditional surgeries,
cardiac surgeons and patients have shifted their preference toward minimally
invasive procedures. Some of the major advantages of MIS are that these
surgeries do not require large incisions; involve low hospitalization
expenditure, due to shorter hospital stay; and lead to faster post-operative
recovery compared to an open surgery. Minimally Invasive Cardiac Surgery/Coronary
Artery Bypass Grafting (MICS CABG) or the McGinn technique, is a heart surgery
performed through several small incisions instead of the traditional open-heart
surgery that requires a median sternotomy approach. Owing to these advantages
of MIS, the patients prefer to opt for these surgeries, over conventional
procedures.
Other than this, increasing awareness about the various treatment
options for cardiovascular diseases, rapid technological advancements, and changing
lifestyles have also been boosting the growth of the cardiovascular devices
market.
However, stringent regulatory policies which delays product launches;
high cost of instruments and their maintenance; lack of skilled professionals;
and unfavorable market conditions for the new players are the major factors
that hinder the growth of the cardiovascular devices market.
Ongoing product approvals in the cardiovascular devices market are expected to
strengthen the position of the market players. For instance, in July 2018,
Medtronic plc received United States Food and Drug Administration (USFDA)
approval for a less-invasive implant approach of its HeartWare HVAD system, a
left ventricular assisted device (LVAD) for patients with advanced heart
failure. It is the smallest commercially available LVAD and has been approved
in the U.S. for implant via thoracotomy, a small lateral surgical incision
between the patient's ribs on the left side of the chest.
Comments
Post a Comment